NTRA

Natera's stock experienced significant growth in the past six months, with a 106.14% increase between September 2025 and September 2026, and a 118.09% increase over the last year. Key events included strong fiscal Q2 2026 financial performance, which surpassed analyst expectations with approximately 40% year-over-year revenue growth and led to a 21.4% stock gain. Expanded regulatory approvals for Signatera, including PMDA approval in Japan for muscle-invasive bladder cancer in September 2026 and colorectal cancer in June 2026, also boosted the stock. Robust clinical data and commercial momentum in oncology, along with positive analyst sentiment, further reinforced investor confidence. However, the stock dropped 12.2% in April 2026 after mixed Q1 2026 financial results, where a widened GAAP net loss exceeded analyst expectations despite revenue growth.